- Conditions
- Chronic Hepatitis C
- Interventions
- PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
- Drug
- Lead sponsor
- Presidio Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Chronic
- Interventions
- Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 6
- States / cities
- La Mesa, California • San Diego, California • DeLand, Florida + 3 more
- Conditions
- Healthy
- Interventions
- BI 207127 NA
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hepatitis C, Chronic
- Interventions
- midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127, Faldaprevir (BI 201335)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 24
- States / cities
- Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 31
- States / cities
- North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- BI 207127, BI 201335, Ribavirin, BI 207217
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more